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Introduction: Physical restraint (PR) use in the intensive care unit (ICU) has been associated with higher rates
of self-extubation and prolonged ICU length of stay. Our objectives were to describe patterns and predictors of
PR use.
Methods: We conducted a secondary analysis of a prospective observational study of analgosedation, antipsychotic,
neuromuscular blocker, and PR practices in 51 Canadian ICUs. Data were collected prospectively for all mechanically
ventilated adults admitted during a two-week period. We tested for patient, treatment, and hospital characteristics that
were associated with PR use and number of days of use, using logistic and Poisson regression respectively.
Results: PR was used on 374 out of 711 (53%) patients, for a mean number of 4.1 (standard deviation (SD) 4.0)
days. Treatment characteristics associated with PR were higher daily benzodiazepine dose (odds ratio (OR) 1.05,
95% confidence interval (CI) 1.00 to 1.11), higher daily opioid dose (OR 1.04, 95% CI 1.01 to 1.06), antipsychotic
drugs (OR 3.09, 95% CI 1.74 to 5.48), agitation (Sedation-Agitation Scale (SAS) >4) (OR 3.73, 95% CI 1.50 to 9.29),
and sedation administration method (continuous and bolus versus bolus only) (OR 3.09, 95% CI 1.74 to 5.48).
Hospital characteristics associated with PR indicated patients were less likely to be restrained in ICUs from
university-affiliated hospitals (OR 0.32, 95% CI 0.17 to 0.61). Mainly treatment characteristics were associated with
more days of PR, including: higher daily benzodiazepine dose (incidence rate ratio (IRR) 1.07, 95% CI 1.01 to
1.13), daily sedation interruption (IRR 3.44, 95% CI 1.48 to 8.10), antipsychotic drugs (IRR 15.67, 95% CI 6.62 to
37.12), SAS <3 (IRR 2.62, 95% CI 1.08 to 6.35), and any adverse event including accidental device removal (IRR
8.27, 95% CI 2.07 to 33.08). Patient characteristics (age, gender, Acute Physiology and Chronic Health Evaluation
II score, admission category, prior substance abuse, prior psychotropic medication, pre-existing psychiatric condition
or dementia) were not associated with PR use or number of days used.
Conclusions: PR was used in half of the patients in these 51 ICUs. Treatment characteristics predominantly predicted PR
use, as opposed to patient or hospital/ICU characteristics. Use of sedative, analgesic, and antipsychotic drugs, agitation,
heavy sedation, and occurrence of an adverse event predicted PR use or number of days used.Introduction
Physical restraint (PR) is applied in the intensive care
unit (ICU) to prevent unplanned treatment interference
that can lead to serious patient harm such as self-
extubation. PR use in the ICU is controversial because
restraints may present an ethical dilemma, conflicting
with values of humane and respectful care; furthermore,* Correspondence: elena.luk@utoronto.ca
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unless otherwise stated.PR can be perceived as barbaric, cruel, and obstructing
patient autonomy [1-5]. PR has been linked to undesir-
able patient outcomes including delirium, post-traumatic
stress disorder, higher rates of self-extubation, and pro-
longed ICU length of stay [6-8].
International descriptions of prevalence of physically
restrained ICU patients vary from 0% to 100% across dif-
ferent countries [9-13]. Numerous policy and guideline
documents aim to minimize PR practice variability and
use [14-18], such as Canada’s province of Ontario’s
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fortunately, few evidence-based recommendations on
methods to minimize restraint use are available due to
the limited number and poor quality of existing studies.
Most studies describe the prevalence, and reasons and
context for PR use, but do not identify modifiable pre-
dictors [9-13,19-22].
We conducted a secondary analysis of PR use in a
large, heterogeneous sample of mechanically ventilated
(MV) patients admitted to 51 Canadian ICUs [23]. Our
objectives were to: (1) describe patterns of PR use in
MV patients (prevalence, number of days of use, number
of episodes of use); and (2) identify patient, treatment,
and ICU/hospital characteristics associated with PR use
and number of days of use.
Previous studies from geriatric and nursing home set-
tings showed non-modifiable patient characteristics,
such as cognitive impairment, may influence PR use
[24,25]. Therefore, we anticipated the latter might pre-
dict PR use in the ICU. As international practice recom-
mendations are to reduce excessive sedation [26], we
hypothesized that sedation practices such as type or dose
of sedative-analgesic or use of sedation minimization
strategies might influence PR practices. Finally, we ex-
pected organizational characteristics might be associated
with PR use, as suggested by survey data [9].
Materials and methods
We conducted a secondary analysis of the I-CAN-SLEAP
database. I-CAN-SLEAP was a prospective, observational
study describing analgo-sedation, antipsychotic, and neuro-
muscular blocker administration and drug assessment or
titration practices in 51 Canadian ICUs [23]. ICUs were re-
cruited from all 10 provinces between 2008 and 2009,
representing university-affiliated and community hospitals.
Patients were included in each ICU during a predefined
two-week period. Patient inclusion criteria were 1) initi-
ation of MV during the inclusion period; and 2)
age ≥16 years. Data were collected from initiation of MV
until extubation, 24 hours after tracheotomy, death, or for
a maximum of 30 days. Each site’s Research Ethics Board
(REB) approved the research protocol and waived the need
for informed consent. An additional file shows a list of all
REBs that approved the study (see Additional file 1).
We collected site level data on hospital and ICU char-
acteristics including province, hospital type (university-
affiliated or community), number of beds (hospital and
ICU), ICU type (for example, medical, surgical), phys-
ician model (open or closed; closed defined as patient
care led by the ICU team), proportion of ventilator-
capable beds in the ICU, and availability of protocols
and assessment scales for sedation, analgesia, and delir-
ium. Nurse-to-patient ratio was collected on each pa-
tient daily.We collected data on baseline patient characteristics
including age, gender, Acute Physiology and Chronic
Health Evaluation (APACHE) II score [27], diagnosis,
comorbidities, medication history, smoking, alcohol, and
prior drug use. Additional daily patient data that we
characterized as treatment characteristics included: PR
use (yes or no); mode of MV; doses of sedative, anal-
gesic, antipsychotic, and neuromuscular blocking drugs;
presence of organ failure; mode of sedation administra-
tion (intermittent use vs. continuous infusion vs. both);
daily sedation interruption (DSI); use of sedation proto-
cols; use of sedation, pain and delirium assessment
scales; and adverse events defined as deliberate or acci-
dental device removal (endotracheal tube, intravenous
catheter, feeding tube and urinary catheter) by patients
or accidental removal by staff, and danger for self or
others. Doses of opioids were converted to morphine
equivalents, and those of benzodiazepines to midazolam
equivalents [28]. All sedation scores were converted to
Sedation-Agitation Scale (SAS) scores [29] and were
classified a priori as: over-sedated (SAS <3), lightly se-
dated (SAS 3 to 4) and agitated (SAS >4). An additional
file describes scale conversions and scoring definitions in
more detail (see Additional file 2).
Statistical analysis
PR prevalence was defined as PR use on at least one day
during the study period. PR prevalence, demographic
characteristics and clinical variables are presented as
means and standard deviations (SD), and frequencies,
proportions and 95% confidence intervals (CIs) for cat-
egorical variables. Demographic characteristics for ‘ever
restrained’ and ‘never-restrained’ patients were com-
pared using chi-square tests for categorical variables and
Wilcoxon rank sum tests or two-sample t tests, depend-
ing on data distribution, for continuous variables.
Using multivariable logistic regression, we assessed pa-
tient, institutional and clinical factors associated with PR
use at any time during the study period, and reported re-
sults using odds ratios (OR) and their associated 95%
CIs. Using Poisson regression analysis, we examined as-
sociations between patient, institutional and clinical vari-
ables and the number of days of PR use, and reported
incidence rate ratios (IRR) and their associated 95% CIs.
Variables entered into each of the two models were se-
lected a priori based on a review of the literature on re-
straint use in diverse populations. Prior to multivariable
modeling, variables were assessed for multicollinearity
using tolerance statistics. A tolerance value of <0.4 was
used to indicate the presence of multicollinearity, which
was not a concern in this analysis. The number of vari-
ables retained in the model was based on rules of model-
ing [30] and these rules were not violated for either
logistic or Poisson model. All tests were two-tailed with







Age (years) 60.6 (16.6) 61.1 (16.8)
Gender (male) 212 (63) 230 (62)
APACHE II score 19.9 (8.0) 19.4 (7.7)
Patient admission category
Medical 124 (37) 156 (42)
Surgical 115 (34) 132 (35)
Cardiac 52 (15) 33 (9)
Neurologic/trauma 35 (10) 41 (11)
Other 11 (3) 12 (3)
Duration of organ dysfunction (days)
Renal failureb 0.9 (2.4) 1.4 (3.3)
Hepatic failurec 0.4 (1.6) 1.0 (3.2)
Inotrope/vasopressor support (days)d 1.4 (2.0) 1.9 (3.1)
Cognitive impairment (dementia) 7 (2) 9 (2)
Psychiatric conditione 45 (13) 53 (14)
Prior use of sedative, opioid,
antidepressant
113 (34) 113 (30)
Prior use of antipsychotic 25 (7) 31 (8)
Current smokers 56 (17) 68 (18)
Alcohol consumption 80 (24) 100 (27)
Habitual drug use 18 (5) 15 (4)
Treatment characteristics
Daily drug use
Benzodiazepines (mgf)* 10.8 (34.0) 29.6 (65.8)
Propofol (mg)* 91.1 (523.5) 104.1 (501.2)
Opioids (mgg)* 32.9 (60.2) 64.6 (91.8)
Daily sedation interruption (days)* 0.7 (1.1) 1.2 (1.7)
Sedation-Agitation Scale scores (days)*
Agitation (SAS >4)h* 0.1 (0.3) 0.4 (1.2)
Over-sedation (SAS <3)h* 1.1 (2.1) 1.9 (2.7)
Antipsychotic administration (days)* 0.2 (0.9) 1.2 (3.0)
Duration of mechanical ventilation (days)* 3.1 (3.5) 6.8 (6.5)
Occurrence of adverse eventi* 9 (3) 24 (6)
aValues are n (%) for categorical variables and means (standard deviations) for
continuous variables; brenal failure was defined as creatinine clearance <30 ml/min,
serum creatinine >180 μmol/L or need for dialysis; chepatic failure was defined as
aspartate aminotransferase (AST) or alanine transaminase (ALT) >2 times the upper
limit of normal or bilirubin >3 times the upper limit of normal; dinotrope or
vasopressor support: administration of inotropes and vasopressors at any dose;
epsychiatric condition included depression, anxiety, bipolar disorder, schizophrenia;
fdose expressed in midazolam equivalents (1 mg midazolam= 0.5 mg lorazepam);
gdose expressed in morphine equivalents (10 mg morphine = 2 mg
hydromorphone = 0.1 mg fentanyl); hSedation-Agitation Scale; iadverse
events comprised deliberate or accidental device removal (endotracheal
tube, intravenous lines, feeding tubes, urinary catheters) by patients or
accidental removal by staff, and danger to self or others. *Difference
between groups was statistically significant (P <0.05). APACHE II, Acute
Physiology and Chronic Health Evaluation II.
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istician conducted all analyses using SAS 9.2 (SAS Insti-
tute, Cary, NC, USA).
Results
PR was used on one or more days for 374/711 patients
(53%, 95% CI 49% to 56%). Patients were restrained on
an average of 4.1 (SD 4.0) days, with a range of 1 to
26 days. Most patients (83%, 311/374) were restrained
only once, the remainder had restraints removed and re-
applied more than once during their ICU admission. Re-
strained and never-restrained patients had similar baseline
characteristics; however, differences in treatment character-
istics were noted (Table 1). Restrained patients experienced
more adverse events, received higher daily doses of benzo-
diazepines, propofol, and opioids, received more days of an-
tipsychotics, experienced DSI more frequently, and were
agitated (SAS >4) and over-sedated (SAS <3) on more days.
PR was used on an average of 76% (95% CI 66% to
85%) of days the patients’ SAS was >4; and 58% (95% CI
51% to 65%) of days the patients’ SAS was <3. PR was
used on an average of 42% (95% CI 34% to 50%) of days
with DSI, 65% (95% CI 55% to 75%) of days an anti-
psychotic was prescribed, and 61% (95% CI 45% to 76%)
of days an adverse event occurred.
Treatment variables independently associated with PR
use comprised: higher benzodiazepine and opioid daily
doses, sedation administration method (continuous and
bolus vs. bolus only), ever receiving an antipsychotic,
and ever scoring SAS >4 (Table 2). For every 10 mg in-
crement in morphine-equivalent dose and for every
10 mg increment in midazolam-equivalent dose, the risk
of PR increased by 4% and 5% respectively. PR use was
less likely in university-affiliated hospitals. Patients were
more likely to be restrained when the ICU proportion of
ventilator-capable beds was >50% and ≤90% as com-
pared to when the ICU proportion of ventilator-capable
beds was <25%. Variables independently associated with
more days of PR use included higher daily benzodiazep-
ine dose, DSI, ever receiving an antipsychotic, SAS <3
and occurrence of an adverse event (Table 3). Patients
were more likely to be restrained for more days in ICUs
where proportion of ventilator-capable beds was 25 to
50% and 76 to 90% compared to ICUs where proportion
of ventilator-capable beds was <25%.
Non-modifiable patient characteristics such as age, gen-
der, APACHE II score, admission category, prior substance
abuse, prior psychotropic medication, and pre-existing psy-
chiatric condition or dementia were not associated with PR
use, nor with the number of days PR was used.
Discussion
This analysis of the I-CAN-SLEAP database describes
prevalence of, and variables associated with, PR use in
Table 2 Factors independently associated with physical
restraint use
Data point Univariable Multivariable
ORa (95% CI) ORa (95% CI)
Patient characteristics
Age 1.00 (0.99-1.01) 1.00 (0.99-1.01)
Male sex 0.98 (0.71-1.33) 1.15 (0.78-1.69)
Psychiatric conditionb 1.02 (0.66-1.56) 0.86 (0.48-1.55)
Cognitive impairment (dementia) 1.01 (0.36-2.81) 1.42 (0.40-5.00)
Prior psychotropic drug usec 0.91 (0.67-1.24) 0.98 (0.64-1.50)
Smoking or alcohol consumption,
habitual drug use
0.99 (0.73-1.36) 1.03 (0.70-1.53)
Patient category
Surgical 1 1
Medical 0.93 (0.66-1.32) 0.96 (0.60-1.52)
Other 0.75 (0.51-1.11) 0.96 (0.58-1.59)
APACHE II score 0.99 (0.97-1.01) 1.00 (0.97-1.02)
Treatment characteristics
Medication use per mechanical
ventilation days
Benzodiazepines (10 mg incrementsd) 1.11 (1.06-1.16) 1.05 (1.00-1.11)
Propofol (10 mg increments) 1.00 (1.00-1.00) 1.00 (1.00-1.00)
Opioids (10 mg incrementse) 1.06 (1.04-1.09) 1.04 (1.01-1.06)
Daily sedation interruption 1.36 (1.00-1.84) 1.46 (0.93-2.30)
Sedation administration
Intermittent use only 1 1
Continuous infusion only 1.43 (0.93-2.21) 1.39 (0.74-2.59)
Both 4.14 (2.45-7.01) 2.71 (1.35-5.43)
Antipsychotic prescription 4.07 (2.50-6.64) 3.09 (1.74-5.48)
Sedation-Agitation Scale scores
Agitation (SAS >4)f 7.31 (3.27-16.36) 3.73 (1.50-9.29)
Over-sedation (SAS <3)f 2.74 (1.83-4.08) 1.30 (0.77-2.20)
Adverse eventg 2.44 (1.12-5.34) 1.29 (0.53-3.15)
Hospital and ICUh characteristics
University-affiliated hospital
(vs. community)
0.71 (0.51-0.99) 0.32 (0.17-0.61)
Closed ICUh model (vs. open model) 1.39 (0.95-2.04) 0.59 (0.34-1.04)
Proportion of ventilator capable
beds in the ICUh
<25% 1 1
25-50% 0.55 (0.25-1.21) 0.99 (0.34-2.85)
51-75% 1.16 (0.52-2.56) 2.97 (1.03-8.55)
76-90% 1.86 (0.83-4.15) 8.34 (2.58-26.99)
>90% 0.63 (0.26-1.52) 1.97 (0.52-7.44)
Nurse to patient ratio ever <1:1 1.50 (1.05-2.15) 0.81 (0.51-1.30)
Province
Ontario 1 1
Newfoundland and Labrador 1.98 (1.00-3.89) 1.55 (0.64-3.77)
Table 2 Factors independently associated with physical
restraint use (Continued)
Nova Scotia 0.49 (0.15-1.67) 0.37 (0.09-1.54)
New Brunswick / /
Prince Edward Island 2.96 (0.79-11.15) 4.23 (0.79-22.64)
Quebec 1.42 (0.93-2.18) 1.80 (0.99-3.29)
Manitoba 4.44 (1.47-13.42) 7.78 (2.13-28.46)
Saskatchewan 0.49 (0.22-1.13) 0.46 (0.15-1.42)
Alberta 0.87 (0.56-1.34) 1.31 (0.67-2.57)
British Columbia 1.38 (0.43-4.45) 1.02 (0.24-4.32)
aOR, odds ratio; bpsychiatric condition included documented depression, anxiety,
bipolar disorder, schizophrenia; cpsychotropic drugs included: sedative, narcotics,
methadone, antidepressants; ddose expressed in midazolam equivalents (1 mg
midazolam=0.5 mg lorazepam); edose expressed in morphine equivalents (10 mg
morphine = 2 mg hydromorphone= 0.1 mg fentanyl); fSedation-Agitation Scale;
gadverse events comprised deliberate or accidental device removal (endotracheal
tube, intravenous lines, feeding tubes, urinary catheters) by patients or accidental
removal by staff, and danger to self or others; hICU, intensive care unit; /, low
frequency counts did not allow for more accurate estimates. APACHE II, Acute
Physiology and Chronic Health Evaluation II.
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of the patients in our study were physically restrained at
least once during the study period. We found that PR
use in Canadian ICUs is frequent despite provincial le-
gislation and national accreditation standards requiring
restraint minimization to maintain patient safety and
provide quality health care [16,31]. Internationally, use
of PR in ICUs is highly variable with recent survey data
and observational studies reporting prevalence rates be-
tween 15% and 100% [9,12,28,32-34]. The highest preva-
lence rates (for example, 90% or 100%) were found in
single ICU settings [9,32].
The most important finding in our study is that pre-
dominantly treatment factors, as opposed to patient or
hospital/ICU factors, influenced the use of PR. Treat-
ment characteristics, specifically higher daily benzodi-
azepine and opioid doses, use of antipsychotics, and the
use of continuous infusions of analgo-sedation were
predictors of PR use. Also, as we hypothesized, SAS
scores >4, representing agitation, predicted PR use. We
also hypothesized that sedation minimization might in-
crease PR use for the same reasons; yet we found that
higher daily opiate and benzodiazepine doses were as-
sociated with PR use. We postulate that agitated pa-
tients received more medications, in combination with
PR, to manage their symptoms. Our data are compar-
able to previous research suggesting that benzodi-
azepine use is more frequent in restrained patients
compared to non-PR patients [21]. Antipsychotic drugs
were more frequently administered to PR patients and
were associated with prolonged PR use, similarly to previ-
ous findings [21]. Patients with antipsychotic prescription
have a 16-fold greater number of restraint days than those
without antipsychotic prescription. As antipsychotic drugs
Table 3 Factors independently associated with number of
days of physical restraints
Data point Univariable Multivariable
IRRa (95% CI) IRRa (95% CI)
Patient characteristics
Age 1.01 (0.99-1.04) 1.00 (0.98-1.03)
Male sex 0.87 (0.37-2.06) 0.73 (0.35-1.54)
Psychiatric conditionb 1.13 (0.35-3.67) 1.27 (0.42-3.84)
Cognitive impairment (dementia) 0.17 (0.01-2.86) 0.28 (0.02-3.40)
Prior psychotropic drug usec 0.60 (0.26-1.41) 0.45 (0.19-1.06)
Smoking or alcohol consumption,
habitual drug use
1.68 (0.71-3.98) 1.55 (0.73-3.27)
Patient category
Surgical 1 1
Medical 1.48 (0.58-3.78) 1.74 (0.72-4.22)
Other 0.58 (0.19-1.72) 0.61 (0.24-1.56)
APACHE II score 0.97 (0.92-1.02) 0.97 (0.92-1.02)
Treatment characteristics




1.11 (1.05-1.17) 1.07 (1.01-1.13)
Propofol (10 mg increments) 1.00 (1.00-1.01) 0.99 (0.99-1.00)
Opioids (10 mg incrementse) 1.05 (1.00-1.01) 1.00 (0.99-1.10)
Daily sedation interruption 9.64 (4.23-21.94) 3.44 (1.46-8.10)
Sedation administration
Intermittent use only 1 1
Continuous infusion only 3.35 (0.93-12.16) 0.87 (0.23-3.22)
Both 23.47 (5.97-92.27) 3.50 (0.88-13.89)
Antipsychotic prescription 45.10 (18.56-109.62) 15.67 (6.62-37.12)
Sedation-Agitation Scale scores
Agitation (SAS >4)f 13.19 (4.12-42.15) 1.99 (0.63-6.27)
Over-sedation (SAS <3)f 11.04 (4.56-26.70) 2.62 (1.08-6.35)
Adverse eventg 20.45 (3.98-105.14) 8.27 (2.07-33.08)
Hospital and ICUh characteristics
University-affiliated hospital
(vs. community)
1.51 (0.63-3.61) 0.46 (0.15-1.43)
Closed ICUh model (vs. open model) 4.06 (1.34-12.26) 0.86 (0.25-3.00)
Proportion of ventilator capable
beds in the ICUh
<25% 1 1
25-50% 7.75 (0.87-69.27) 15.82 (1.65-151.84)
51-75% 1.97 (0.23-16.68) 5.99 (0.66-54.01)
76-90% 7.66 (0.92-63.51) 31.76 (3.02-334.41)
>90% 1.90 (0.16-22.47) 10.31 (0.67-157.93)
Nurse to patient ratio ever <1:1 2.73 (1.08-6.89) 1.75 (0.75-4.13)
Province
Ontario 1 1
Table 3 Factors independently associated with number of
days of physical restraints (Continued)
Newfoundland and Labrador 3.63 (0.35-38.16) 3.59 (0.34-37.48)
Nova Scotia 0.19 (0.00-14.37) 1.87 (0.04-97.96)
New Brunswick 0.53 (0.01-39.05) 0.83 (0.01-46.75)
Prince Edward Island 0.89 (0.04-21.49) 7.47 (0.42-133.77)
Quebec 2.74 (0.35-21.55) 2.19 (0.31-15.38)
Manitoba 1.40 (0.06-33.51) 8.95 (0.38-212.36)
Saskatchewan 0.44 (0.05-3.71) 1.56 (0.17-14.82)
Alberta 1.49 (0.05-47.70) 0.85 (0.04-20.32)
British Columbia 1.10 (0.16-7.64) 0.93 (0.15-5.61)
aIRR, incidence rate ratio; bpsychiatric condition included documented depression,
anxiety, bipolar disorder, schizophrenia; cpsychotropic drugs included: sedative,
narcotics, methadone, antidepressants; ddose expressed in midazolam equivalents
(1 mg midazolam=0.5 mg lorazepam); edose expressed in morphine equivalents
(10 mg morphine = 2 mg hydromorphone= 0.1 mg fentanyl); fSedation-Agitation
Scale; gadverse events comprised deliberate or accidental device removal
(endotracheal tube, intravenous lines, feeding tubes, urinary catheters) by patients or
accidental removal by staff, and danger to self or others; hICU, intensive care unit.
APACHE II, Acute Physiology and Chronic Health Evaluation II.
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been a proxy for hyperactive delirium in this study. Some
reports have identified associations between PR use and
delirium in the ICU; for example, PR patients were more
often found to be delirious than non-PR patients [21], a
greater number of patients with delirium received PR and
for longer durations than patients without delirium [35],
and PR use was associated with an increased risk of
delirium [7].
The current trend in sedation practice is to target light
sedation levels using strategies such as DSI or nurse-
driven sedation titration protocols to achieve improved
clinical outcomes such as reduced length of stay [26]. A
recent randomized controlled trial of protocolized sed-
ation versus protocolized sedation plus DSI, with a light
target level of sedation, found no significant differences
in the prevalence of PR (79.4% vs. 76.4%, P = 0.46), nor
in the duration of PR use (5.36 days (6.14) vs. 4.71 days
(5.67), P = 0.56) between the two groups [28]. In our
study, DSI was not a predictor of PR use, but was associ-
ated with a 3.4 times increase in the number of days of
PR use. Although we did not seek the reasons for re-
straint application, we hypothesize that agitation and
treatment interference were anticipated by nurses for pa-
tients undergoing DSI, a concern which has been previ-
ously reported [36]. Similarly, in our study, agitation was
associated with an increased risk of PR use. Conversely,
over-sedation was associated with a longer duration of
PR use, suggesting failure to discontinue PR when it
may no longer be justified.
Adverse events such as self-extubation were not asso-
ciated with PR use in this study, but were associated
with the number of days of PR use. Several cohort stud-
ies have identified the failure to use PRs as contributing
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not found PR use associated with less self-extubation. A
recent systematic review of unplanned extubation in the
ICU found between 25% and 87% of patients were phys-
ically restrained at time of unplanned extubation [40].
Further, one case-control study identified use of PR as
associated with an increased risk of self-extubation (OR
3.1, 95% CI 1.71 to 5.70) [6]. Patients from university-
affiliated hospitals were less likely to be restrained, and
restrained for shorter durations. University-affiliated
hospitals may use PRs less often if the clinicians working
in these hospitals are more familiar with evidence-based
practices or have restraint reduction protocols in place.
Low nurse-patient ratios were previously described as
potentially increasing PR use [9], but we found no asso-
ciation of PR use with nurse-patient ratio. However, this
may be due to the maintenance of one-to-one nurse-
patient ratios for most patient days in our study, con-
trasting with the heterogenous (from 1:1 to 1:4) and on
average lower nurse-patient ratios reported in European
centers [9].
Our study has limitations. Data collectors were not
provided with a definition of PR, and as such, we cannot
ascertain whether devices such as splints, intravenous
arm boards, or mittens were considered as PR. PR use
was recorded only once daily as a binary variable; and
duration of PR use (from initiation to discontinuation)
was not captured. Therefore, occurrence of more than
one episode of PR in a single day was not recorded. We
cannot establish the temporal relationship between risk
factors and PR use. For example, future studies should
aim to determine the directionality of the relationship
between delirium and PR (that is, whether delirium leads
to PR use or whether PR use contributes to the develop-
ment of delirium) or if the relationship is bidirectional.
Additionally, we are unable to address the confound-
ing of sedative drugs and PR. Sedatives and analgesics
are used to treat agitation, anxiety, and pain in the ICU
patient, but are also considered as chemical restraints,
used concurrently with or alternatively to PRs. As such,
future observational studies prospectively designed to
explore whether use of sedative or analgesic drugs first
contribute to agitation requiring use of PR or vice versa
would be valuable. While we recorded the use of delir-
ium scales, we did not record positive delirium screen-
ing. We do not know which hospitals or ICUs in our
study had PR policies and protocols in place. Previous
studies found that organizational or unit restraint pol-
icies and protocols may influence PR use [41,42].
Strengths of our study include the large sample size,
multicenter and national representation, and a heteroge-
neous sample of ICUs and patients based on broad in-
clusion criteria, which enhance the generalizability of
our data. Furthermore, data were collected prospectively,and did not rely on retrospective chart review or clini-
cians’ perceptions. Finally, to our knowledge, this is the
first study examining predictors of PR use and number
of days of use in the ICU.
Conclusions
PR use in Canadian ICUs is common, despite legislation
and guidelines to minimize use. We found that treat-
ment characteristics specifically use of benzodiazepines,
opioids, and antipsychotics, agitation, heavy sedation,
sedation administration method, DSI, and occurrence of
an adverse event were associated with PR use or the
number of days of PR use. Understanding predictors of
PR use in the ICU may increase awareness of patients at
risk of receiving restraints, and enable researchers to
tailor future interventions to reduce modifiable use.
Key messages
 We found that 53% of patients in the I-CAN-SLEAP
study were restrained.
 Physical restraint use in Canadian ICUs is common
despite guidelines to minimize use.
 This study adds to the body of literature on the
subject of physical restraint by examining predictors
of use.
 Treatment characteristics that influence sedation
and agitation were predominantly associated with
physical restraint use and number of days of use.
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